Monday, October 6, 2008

7:45 – 8:30 am

Registration & Continental Breakfast

8:30 – 8:35

Welcome & Opening Remarks - Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation

8:35 – 8:55

Plenary Talk: Neurobiology of Memory and Learning: Implications for Alzheimer's Disease and Cognitive Aging - Ottavio Arancio, MD, PhD, Columbia University

I. Neuroprotection

   Chair: Frank Longo, MD, PhD, Stanford University & PharmatrophiX

8:55 – 9:00

Session Overview – Frank Longo, MD, PhD

9:00 – 9:20

Inhibition of Alzheimer-Related Neurodegeneration by Small Molecule Neurotrophin Receptor Ligands - Frank Longo, PhD, Stanford University and PharmatrophiX

9:20 – 9:30

Q&A

9:30 – 9:50

Efficacy of Trk-A-Targeted Neuroprotective Drugs in a Mouse Model of AD - Horacio Uri Saragovi, PhD, Lady Davis Institute for Medical Research

9:50 – 10:00

Q&A

10:00 –  10:20

Screening for Alzheimer Therapeutics Based on a Novel Target - Varghese John, PhD, Buck Institute

10:20 – 10:30

Q&A

10:30 – 10:50

Inhibition of Rho Signaling to Prevent Dendritic and Synapse Loss in AD -Anthony Koleske, PhD, Yale University

10: 50 – 11:00

Q&A

11:00 – 11:10

BREAK

11:10 – 11:30

Updates on AL-108: Case Study for Drug Discovery and Development toward Cognitive Enhancement and Neuroprotection - Illana Gozes, PhD, Tel Aviv University and Allon Therapeutics, Inc.

11:30 – 11:40

Q&A

11:40 am  – 12:00 pm

Chromatin Remodelers for Recovery of Learning and Memory - Alan Kozikowski, PhD, University of Illinois at Chicago

12:00 – 12:10

Q&A

12:10 – 12:30

G-CSF Reduces Brain Amyloid, Increases Expression of Synaptophysin and Improves Cognition in a Mouse Model of AD - Juan Sanchez-Ramos, MD, PhD,  University of South Florida

12:30 – 12:40

Q&A

12:40 – 1:05

Allopregnanolone Regulation of Neurogenesis, Alzheimer’s Pathology Burden and Cognition in the Aging Male Triple Trangenic Mouse Model of Alzheimer’s Disease - Roberta Brinton, PhD, University of Southern California

1:05 – 1:15

Q&A

1:15 – 2:15

LUNCH

II. Anti-Amyloid and Misfolding

    Chair: Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

2:15 – 2:20

Session Overview – Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

2:20 – 2:40

Anti-amyloidogenic Effects of Noradrenaline and PPARdelta Agonists - Douglas Feinstein, PhD, University of Illinois

2:40 – 2:50

Q&A

2:50 – 3:10

Validation and Optimization of Stable Isotope Labeling Kinetic Analysis of Amyloid Beta from Human Cerebrospinal Fluid- Randall Bateman, MD, Washington University School of Medicine and C2N Diagnostics

3:10 – 3:20

Q&A

3:20 – 3:40

New Immune Modulators of Alzheimer’s Disease - John Cashman, PhD, Human Biomolecular Research Institute

3:40 – 3:50

Q&A

3:50 – 4:00

BREAK

4:00 – 4:20

Understanding the Structural Basis for the Association of ApoE4 with Alzheimer’s Disease: Opening the Door for Therapeutic Approaches - Karl H. Weisgraber, PhD, Gladstone Institute of Neurological Disease

4:20 – 4:30

Q&A

4:30 – 4:50

A Novel Combined Experimental Therapy in an Alzheimer’s Transgenic Model - A. Claudio Cuello, MD, Dsc, FRSC, McGill University

4:50 – 5:00

Q&A

5:00 – 5:20

Development of Hsp90 Inhibitors as Novel Therapies for AD - Gabriela Chiosis, PhD, Memorial Sloan-Kettering Cancer Center

5:20 – 5:30

Q&A

5:30 – 5:50

ApoE Therapeutics - Daniel Laskowitz, MD, MHS, Duke University Medical Center

5:50 – 6:00

Q&A

6:00 – 6:05

Closing Remarks - Diana Shineman, PhD, Alzheimer's Drug Discovery Foundation

6:05 – 7:30

NETWORKING RECEPTION

Tuesday, October 7, 2008

8:00 – 8:30 am

Continental Breakfast

8:30 – 8:50

Phosphodiesterases and Synaptic Plasticity: Novel Approaches to the Treatment of Alzheimer’s Disease - Thomas Lanz, PhD, Pfizer

III. Anti-Tangles & Frontotemporal Dementia

     Chair: Jeff Kuret, PhD - Ohio State University

8:50 – 8:55

Session Overview – Jeff Kuret, PhD

8:55 – 9:15

Optimization of Pharmacokinetic and Pharmacodynamic Properties of a Small Molecule O-GlcNAcase Inhibitor for Treatment of Frontotemporal Dementia - David Vocadlo, PhD, Simon Fraser University

9:15 – 9:25

Q&A

9:25 – 9:45

Testing of New Lysosomal Modulatory Drugs for Reducing Tau Aggregates and Other AD-Related Changes - Ben Bahr, PhD, University of Connecticut

9:45 – 9:55

Q&A

9:55 – 10:15

Tau Aggregate Inhibitors: a Medicinal Chemistry Point of View - Jeff Kuret, PhD, Ohio State University

10:15 – 10:25

Q&A

10:25 – 10:45

Tau-Focused Vaccine Therapy for AD and Related Tauopathies - Einar Sigurdsson, PhD, New York University Medical Center

10:45 – 10:55

Q&A

10:55  – 11:05

BREAK

11:05  – 11:25

MARK as a Target for Neurodegenerative Disease - Eva-Maria Mandelkow, MD, PhD, Max-Planck Unit for Structural Molecular Biology

11:25 – 11:35

Q&A

IV. Anti-inflammatory & Anti-oxidant Strategies

      Chair: D. Martin Watterson, PhD, Northwestern University

11:35  – 11:40

Session Overview – D. Martin Watterson, PhD

11:40 am – 12:00 pm

Suppression of Glial HO-1 Activitiy as a Potential Neurotherapeutic Intervention in AD - Hyman Schipper, MD, PhD, FRCPC, Osta Biotechnologies Inc.

12:00 – 12:10

Q&A

12:10 – 12:30 pm

Gene-Regulating Protein Kinase Inhibitors as Potential AD Therapeutics - D. Martin Watterson, PhD, Northwestern University

12:30 – 12:40

Q&A

12:40 – 1:40

LUNCH

1:40 – 2:00

NADPH Oxidase as a Therapeutic Target in Alzheimer’s Disease -  Michelle Block, PhD, Virginia Commonwealth University

2:00 – 2:10

Q&A

2:10 – 2:30

KIBRA as a Novel Target for Alzheimer’s Disease - Karoly Nikolich, PhD, Amnestix, Inc.

2:30 – 2:40

Q&A

2:40 – 3:00

Small Molecule TNF-Alpha Inhibitors for Alzheimer's Disease - S. Prasad Gabbita, PhD, P2D Biosciences

3:00 – 3:10

Q&A

3:10 – 3:30

Novel Therapeutic Approaches Constituting Multimodal Drugs for Alzheimer’s Disease  - Moussa B.H. Youdim, PhD, Technion-Israel Institute of Technology

3:30 – 3:40

Q&A

3:40 – 3:50

Closing Remarks - Howard Fillit, MD, Executive Director, Alzheimer's Drug Discovery Foundation